Description

Daprodustat 1mg Tablets

Daprodustat 1mg Tablets represent a modern pharmacological approach to treating anemia associated with chronic kidney disease (CKD). Unlike traditional injectable treatments that mimic erythropoietin directly, this medication belongs to a class of drugs known as hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI).

The mechanism of action is designed to simulate the body’s natural response to low oxygen levels (hypoxia). In normal oxygen conditions, an enzyme called prolyl hydroxylase breaks down HIF, a protein that triggers red blood cell production. By inhibiting this enzyme, Daprodustat 1mg Tablets allow HIF to accumulate. This accumulation signals the body to increase the production of endogenous erythropoietin in the liver and kidneys, while also improving iron transition and utilization. By harnessing this internal pathway, the medication effectively raises and maintains hemoglobin levels through oral administration, offering a significant alternative to erythropoiesis-stimulating agents (ESAs) that require subcutaneous or intravenous injections.

Indications / Uses of Daprodustat 1mg Tablets

Daprodustat 1mg Tablets are indicated for the treatment of anemia caused by chronic kidney disease in adult patients. Specific clinical applications include:

• Dialysis-Dependent Patients: Primarily indicated for adults who have been receiving dialysis for at least four months. It helps stabilize hemoglobin levels within a target range to reduce the need for blood transfusions.
• Alternative to Injectables: Used as an oral substitute for patients who find regular injections of traditional ESAs difficult or inconvenient.
• Hemoglobin Management: Indicated to increase or maintain hemoglobin levels to help alleviate symptoms of anemia, such as extreme fatigue and shortness of breath.
• Fine-Tuning Dosage: The 1mg strength is a critical tool for healthcare providers to precisely titrate the dose, allowing for small adjustments to keep hemoglobin within the recommended therapeutic window (usually 10 to 11 g/dL).

Key Features

• Oral Administration: As a tablet taken once daily, it eliminates the “needle burden” associated with traditional anemia treatments, which is particularly beneficial for home-care settings.
• Physiological Approach: By stimulating the body’s own erythropoietin production, it provides a more gradual and natural rise in red blood cell counts compared to the rapid spikes sometimes seen with injectable agents.
• Iron Regulation: HIF-PH inhibitors can decrease hepcidin levels, a protein that blocks iron absorption. This helps the body better utilize existing iron stores for making new red blood cells.
• No Refrigeration Required: Unlike many injectable biologics, Daprodustat 1mg Tablets are chemically stable at room temperature, making storage and travel much simpler for the patient.

Storage for Daprodustat 1mg Tablets

To ensure the stability and potency of Daprodustat 1mg Tablets, proper storage is essential. Store the medication at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Brief excursions are permitted between 15°C and 30°C (59°F to 86°F). It is important to keep the tablets in their original container to protect them from moisture and light. Do not store the medication in humid areas like bathrooms. Ensure the bottle is tightly closed and kept securely out of the reach and sight of children and pets.

Important Note on Daprodustat 1mg Tablets

Treatment with Daprodustat 1mg Tablets must be strictly supervised by a healthcare professional, as the drug carries a Boxed Warning regarding an increased risk of serious cardiovascular events, including heart attack, stroke, and blood clots. Hemoglobin levels must be monitored frequently (typically every two weeks during initiation) to ensure they do not rise too quickly or exceed the target range.

The medication is not recommended for patients with primary bone marrow failure or those with certain types of cancer, as it may stimulate tumor growth. Common side effects include high blood pressure (hypertension), thrombotic vascular events, and abdominal pain.

Daprodustat can interact with other drugs. It is primarily metabolized by CYP2C8; therefore, taking it with strong CYP2C8 inhibitors (such as gemfibrozil) can significantly increase the drug’s levels in the blood and should be avoided. Patients should also inform their doctor of any history of liver disease, as this may affect how the drug is processed. If a dose is missed, it should be skipped, and the next dose taken at the regular time; never double the dose.